Evaluation of manidipine hydrochloride, a new calcium antagonist, in the treatment of hypertensive patients with renal disorders
| Autor: | Michihiko Takahashi, Kenji Mizuno, Hiroshi Haga, Soitsu Fukuchi |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Pharmacology
Creatinine medicine.medical_specialty business.industry medicine.drug_class Diastole Urology Renal function Calcium channel blocker Manidipine chemistry.chemical_compound Endocrinology Blood pressure chemistry Tolerability Internal medicine medicine Pharmacology (medical) Adverse effect business medicine.drug |
| Zdroj: | Current Therapeutic Research. 52:248-253 |
| ISSN: | 0011-393X |
| DOI: | 10.1016/s0011-393x(05)80475-8 |
| Popis: | The antihypertensive effectiveness, tolerability, and safety of manidipine hydrochloride, a newly synthesized calcium channel blocker, were evaluated in 16 hypertensive patients (10 men and 6 women, ages 35 to 80 years) with renal disorders. Manidipine treatment (10 or 20 mg/day once daily for 12 weeks) produced a significant reduction in both systolic and diastolic blood pressures, from a baseline value of 174.4 ± 3.0/98.4 ± 3.0 mmHg to 146.9 ± 3.2/87.1 ± 2.1 mmHg, after 4 weeks of therapy. The antihypertensive effect was well tolerated and sustained during administration. Biochemical variables, including serum creatinine, were unaltered by the therapy. In addition, renal function assessed by the urinary excretion rate of phenolsulfonphthalein did not deteriorate during manidipine therapy despite a marked reduction in blood pressure. No severe adverse effects were noted during the trial. We conclude that manidipine is a safe and effective antihypertensive agent for the treatment of patients with hypertension and renal disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|